S100A10 and breast carcinoma: Interestingly, we also observed that the breast cancer cell line MDA MB 231 that expresses oncogenic KRAS (which is not a commonly acquired mutation in this type of cancer) shows higher levels of expression of S100A10 compared to the breast cancer cell line MCF7 that express WT KRAS (Supplementary Figure S5).